Global Genetic Testing Market Size, Share, Opportunities, COVID 19 Impact, And Trends By Type (Prenatal Testing, New Born Screening, Diagnostic Testing, Carrier Testing, Predictive & Pre-symptomatic Testing), By Diseases (Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne’s Muscular Dystrophy, Alzheimer’s Diseases, Thalassemia, Huntington’s Disease, Others), By Technology (Introduction, Cyto-Genetics Testing, Biochemical Testing, Molecular Testing), And By Geography - Forecasts From 2019 To 2024

Published:  May 2021 Report Code: KSI061610991 Pages: 130

The global genetic testing market is projected to expand at a CAGR of 13.17% during the forecast period to reach US$8.162 billion by 2024 from US$3.885 billion in 2018. The global genetic testing demand is driven by a number of factors such as the aging global population, rising incidences of genetic and hereditary diseases, growing awareness, technological advancements, and rise in the application of genetic testing for the early detection of various diseases.

With the development of new technologies and innovation in both scientific research and research equipment, genetic testing is headed towards an era of high significance in the near future.  As investments in research and development related to genetic testing increase, the global genetic testing market is expected to witness a substantial boost in its overall growth in the next five years.

Geographical Analysis

North America holds the largest share in the global genetic testing market owing to technological advancements, the rising prevalence of genetic diseases, and the high quality of infrastructure to support the genetic testing industry in the region. However, emerging economies hold good potential for the growth of the genetic testing market due to factors such as rising patient pool, more government funding supporting the investment in the industry, and growing awareness regarding the technology. APAC region will witness the fastest market growth owing to the rising aging population, rising purchasing power, and technological advancements in the region. However, the high cost of genetic testing coupled with unclear reimbursement structure, lack of skilled personnel, and lack of regulations in the market will restrain the growth of this market during the forecast period.

Research Methodology

The report provides a brief introduction of the market and deals with detailed research methodology for calculating market size and forecasts, secondary data sources used and the primary inputs which were taken for data validation. This section also outlines various segments which have been covered as part of the report.

Market Dynamics

The next section provides comprehensive market dynamics through an overview section along with growth drivers, challenges, and opportunities that exist in the current market. This section of the report also provides global and regional regulations which are determining the market growth and industry value chain analysis of the genetic testing market. Complete industry analysis has also been covered by Porter’s five forces model as a part of this report section.

Competitive Insight

The major players discussed in this report include F. Hoffmann-La Roche Ltd, 23&Me, Inc., Precipio, Inc., AutoGenomics, Abbott Laboratories, Luminex Corporation with few others.

 

Global Genetic Testing Market Scope:
Report Metric Details
 Market size value in 2018  US$3.885 billion
 Market size value in 2024  US$8.162 billion
 Growth Rate  CAGR of 13.17% from 2018 to 2024
 Base year  2018
 Forecast period  2019–2024
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Diseases, Technology, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  F. Hoffmann-La Roche Ltd, Abbott Laboratories, Precipio, Inc., Ariosa Diagnostics,   Inc., Biocartis SA, Cepheid, 23&Me, Inc., Luminex Corporation, Sequenom, Inc,   AutoGenomics, Illumina, Inc 
 Customization scope  Free report customization with purchase

 

Segmentation

The genetic testing market has been segmented by product type, by diseases, by technology, and geography:

By Type

Prenatal Testing

New Born Screening

Diagnostic Testing

Carrier Testing

Predictive & Pre-symptomatic Testing

 

By Diseases

Cancer

Cystic Fibrosis

Sickle Cell Anemia

Duchenne’s Muscular Dystrophy

Alzheimer’s Diseases

Thalassemia

Huntington’s Disease

Others

 

By Technology

Introduction

Cyto-genetics Testing

Biochemical Testing

Molecular Testing

 

By Geography

North America

United States

Canada

Mexico

Others

South America

Brazil

Argentina

Others

Europe

United Kingdom

Germany

France

Italy

Others

Middle East and Africa

Asia Pacific

Japan

China

India

Australia

Others


Frequently Asked Questions (FAQs)

Q1. What are the growth prospects for genetic testing market?
A1. The global genetic testing market is projected to expand at a CAGR of 13.17% during the forecast period.
 
Q2. What will be the genetic testing market size by 2024?
A2. The genetic testing market is projected to reach a total market size of US$8.162 billion by 2024.
 
Q3. What is the size of global genetic testing market?
A3. Genetic Testing market was valued at US$3.885 billion in 2018. 
 
Q4. What factors are anticipated to drive the genetic testing market growth?
A4. The global genetic testing demand is driven by a number of factors such as the aging global population, rising incidences of genetic and hereditary diseases, growing awareness, technological advancements, and a rise in the application of genetic testing for early detection of various diseases.
 
Q5. Which region holds the largest market share in the genetic testing market?
A5. North America holds the largest share in the global genetic testing market owing to technological advancements, the rising prevalence of genetic diseases, and the high quality of infrastructure to support the genetic testing industry in the region.
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY  
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Product Pipeline
4.7. Life Cycle Analysis - Regional Snapshot
4.8. Market Attractiveness
5. GLOBAL GENETIC TESTING MARKET BY TYPE
5.1. Prenatal Testing
5.2. Newborn Screening
5.3. Diagnostic Testing
5.4. Carrier Testing
5.5. Predictive & Presymptomatic Testing
6. GLOBAL GENETIC TESTING MARKET BY DISEASE
6.1. Cancer
6.2. Cystic Fibrosis
6.3. Sickle Cell Anemia
6.4. Duchenne Muscular Dystrophy
6.5. Alzheimer Disease
6.6. Thalassemia
6.7. Huntington Disease
6.8. Others
7. GLOBAL GENETIC TESTING MARKET BY TECHNOLOGY
7.1. Cytogenetic Testing
7.2. Biochemical Testing
7.3. Molecular Testing
8. GLOBAL GENETIC TESTING MARKET BY GEOGRAPHY
8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil 
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. United Kingdom
8.3.2. Germany 
8.3.3. France 
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.5. Asia Pacific
8.5.1. Japan
8.5.2. China
8.5.3. India
8.5.4. Australia
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Recent Deals and Investment
9.3. Strategies of Key Players
10. COMPANY PROFILES
10.1.  F.Hoffmann-La Roche Ltd
10.1.1. Company Overview
10.1.2. Financials
10.1.3. Products and Services
10.1.4. Recent Developments
10.2.  Abbot 
10.2.1. Company Overview
10.2.2. Financials
10.2.3. Products and Services
10.2.4. Recent Developments
10.3.  Pecipio Inc.
10.3.1. Company Overview
10.3.2. Financials
10.3.3. Products and Services
10.3.4. Recent Developments
10.4.  Ariosa Diagnostic Inc.
10.4.1. Company Overview
10.4.2. Financials
10.4.3. Products and Services
10.4.4. Recent Developments
10.5.  Biocartis
10.5.1. Company Overview
10.5.2. Financials
10.5.3. Products and Services
10.5.4. Recent Developments
10.6. Cepheid 
10.6.1. Company Overview
10.6.2. Financials
10.6.3. Products and Services
10.6.4. Recent Developments
10.7. 23andMe, Inc.
10.7.1. Company Overview
10.7.2. Financials
10.7.3. Products and Services
10.7.4. Recent Developments
10.8. Luminex Corporation
10.8.1. Company Overview
10.8.2. Financials
10.8.3. Products and Services
10.8.4. Recent Developments
10.9. Sequenom, Inc.
10.9.1. Company Overview
10.9.2. Financials
10.9.3. Products and Services
10.9.4. Recent Developments
10.10. AutoGenomics
10.10.1. Company Overview
10.10.2. Financials
10.10.3. Products and Services
10.10.4. Recent Developments
10.11. Illumina, Inc.
10.11.1. Company Overview
10.11.2. Financials
10.11.3. Products and Services
10.11.4. Recent Developments
LIST OF FIGURES
LIST OF TABLES
 
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Precipio, Inc.
Ariosa Diagnostics, Inc.
Biocartis SA
Cepheid
23&Me, Inc.
Luminex Corporation
Sequenom, Inc
AutoGenomics 
Illumina, Inc 

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us